Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2008

01-06-2008 | Research Article

Change of body weight and lifestyle of persons at risk for diabetes after screening and counselling in pharmacies

Authors: Andrea Botomino, Rudolf Bruppacher, Stephan Krähenbühl, Kurt E. Hersberger

Published in: International Journal of Clinical Pharmacy | Issue 3/2008

Login to get access

Abstract

Objective To investigate the effects of pharmacy based counselling on changes in lifestyle and body weight. Methods Three months after screening a stratified sample of 3,800 randomly chosen overweight persons were addressed with questionnaires. Half a year and 1 year later the assessment was repeated. Standard counselling (SC; non-specific recommendations towards lifestyle), intensive counselling (IC; additional advice to reduce body weight) and counselling for persons at high risk for type 2 diabetes (HRC; recommendation to contact a physician) were compared. Results All counselling groups (SC; n = 557, IC; n = 568, HRC; n = 245) showed significant weight loss three months after screening (0.6–1.9 kg). A further weight reduction was observed at 1 year follow up (1.1–2.4 kg). The HRC group showed a higher percentage of weight loss than the IC or SC group after 3 months (−2.25% vs. −1.20% and −0.67%; P < 0.001) and at 1 year of follow-up (−2.74% vs. −1.54% and −1.29%; P < 0.01). Lifestyle changes in physical activity and/or nutrition were reported by 81.2% in the HRC group, 74.1% in the IC group and 67.0% in the SC group. Conclusion Immediate counselling in community pharmacies after screening for type 2 diabetes can result in significant lifestyle changes and weight loss in overweight individuals.
Literature
1.
go back to reference Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343–50.PubMedCrossRef Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343–50.PubMedCrossRef
2.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403.PubMedCrossRef Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403.PubMedCrossRef
3.
go back to reference Hersberger KE, Botomino A, Mancini M, Bruppacher R. Sequential screening for diabetes—evaluation of a campaign in Swiss community pharmacies. Pharm World Sci 2006;28(3):171–9.PubMedCrossRef Hersberger KE, Botomino A, Mancini M, Bruppacher R. Sequential screening for diabetes—evaluation of a campaign in Swiss community pharmacies. Pharm World Sci 2006;28(3):171–9.PubMedCrossRef
4.
go back to reference Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot 1997;12(1):38–48.PubMed Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot 1997;12(1):38–48.PubMed
5.
go back to reference James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000;356(9248):2119–25.PubMedCrossRef James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000;356(9248):2119–25.PubMedCrossRef
6.
go back to reference Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352(9123):167–72.PubMedCrossRef Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352(9123):167–72.PubMedCrossRef
7.
go back to reference Dzien A, Dzien-Bischinger C, Lechleitner M. Seasonal fluctuation in body mass index. Clin Nutr. 2003;22(4):425–6.PubMedCrossRef Dzien A, Dzien-Bischinger C, Lechleitner M. Seasonal fluctuation in body mass index. Clin Nutr. 2003;22(4):425–6.PubMedCrossRef
8.
go back to reference Visscher TL, Seidell JC. Time trends (1993–1997) and seasonal variation in body mass index and waist circumference in the Netherlands. Int J Obes Relat Metab Disord 2004. Visscher TL, Seidell JC. Time trends (1993–1997) and seasonal variation in body mass index and waist circumference in the Netherlands. Int J Obes Relat Metab Disord 2004.
9.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–421. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–421.
10.
go back to reference Ahrens RA, Hower M, Best AM. Effects of weight reduction interventions by community pharmacists. J Am Pharm Assoc (Wash) 2003;43(5):583–9. Ahrens RA, Hower M, Best AM. Effects of weight reduction interventions by community pharmacists. J Am Pharm Assoc (Wash) 2003;43(5):583–9.
Metadata
Title
Change of body weight and lifestyle of persons at risk for diabetes after screening and counselling in pharmacies
Authors
Andrea Botomino
Rudolf Bruppacher
Stephan Krähenbühl
Kurt E. Hersberger
Publication date
01-06-2008
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 3/2008
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-007-9174-3

Other articles of this Issue 3/2008

International Journal of Clinical Pharmacy 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.